Bristol Melanoma Drug's Advisory Panel Delayed Following Review Date Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional Phase III data for ipilimumab might be available by next year, and an early March advisory committee date now looks likely, given the rescheduled PDUFA date of March 26, 2011.